Cadrenal Therapeutics regains Nasdaq minimum bid price compliance

Cadrenal Therapeutics, Inc.

Received Nasdaq letter on Sept 5 confirming closing bid price >=$1 for 10 consecutive business days (Aug 20-Sept 4).
Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and the matter is closed.
No further action required; stock continues trading on Nasdaq Capital Market under CVKD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.